Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

North Shields, United Kingdom Clinical Trials

A listing of North Shields, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (16) clinical trials

A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Parts A and B will consist of 3 periods: Screening, Treatment and Follow-up. Screening Period The Screening Period starts 28 days ( 3 days) prior to first dose of CC-90011. The informed consent document (ICD) must be signed and dated by the subject and the administering staff prior to the ...

Phase

5.74 miles

Learn More »

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

Phase

5.74 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

5.74 miles

Learn More »

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

A Phase I study to assess the systemic exposure, effiacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) ...

Phase

5.74 miles

Learn More »

MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study

This clinical trial will investigate the safety and activity of MEN1309 in patients with CD205-positive metastatic solid tumors and Non-Hodgkin Lymphoma who have tried other types of treatment for cancer without adequate response (or the cancer came back). CD205 is a protein present in certain types of cancer. This is ...

Phase

5.74 miles

Learn More »

A CR-UK Phase I Trial of LY3143921

This clinical study is looking at a drug called LY3143921 hydrate (a Cdc7 inhibitor). Cdc7 helps our cells replicate correctly. In normal cells, Cdc7 is usually found at a low level, but can reach higher levels in cancer cells. This is often the case in certain types of solid tumour ...

Phase

5.74 miles

Learn More »

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Part 1 followed a rolling six dose escalation schedule of AZD3965 until the maximum tolerated dose (MTD) was defined. 43 patients with advanced solid tumours were treated in Part 1 of the study. A recommended Phase II dose (RP2D) has been proposed from the safety, pharmacokinetic, and proof of mechanism ...

Phase

5.74 miles

Learn More »

A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs) Participants With Ulcerative Colitis (UC) and Participants With Crohn's Disease (CD)

This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A. The study will consist of a repeat dose escalation in HVs, in participants with UC, and in participants with CD across multiple sites.

Phase

7.03 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Phase

7.03 miles

Learn More »

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Expansion Phase of the study: Subjects must have relapsed/refractory RMS or a solid malignant tumor (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor).

Phase

7.03 miles

Learn More »